As of Nov 19, 2026, 2 of 2 active firms rate CHRS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CHRS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.20
Range $-0.20 – $-0.20 · 1 analysts · -20% YoY
Next period, 1 analysts expect Coherus BioSciences Inc to earn $-0.20 a share (range $-0.20 – $-0.20), versus $-0.25 a year earlier. Full-year consensus is $-0.90, growing to $-0.62 the year after.
REVENUE · NEXT QUARTER
$19.2M
Range $17.3M – $20.5M · 1 analysts · +56% YoY
Revenue is expected to reach $19.2M (range $17.3M – $20.5M), +55.8% year-over-year. Full-year consensus is $56.7M, rising to $87.5M next year.
Top analysts covering Coherus BioSciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CHRS.
#1
Douglas Tsao
HC Wainwright & Co. · Rank #312
Buy
$7.00+1615.3% to target
Overall win rate
35%
+ Follow
#2
Jay Olson
Oppenheimer · Rank #484
Buy
$10.00+2350.4% to target
Overall win rate
31%
+ Follow
#3
Jason McCarthy
Maxim Group · Rank #567
Buy
$4.00+880.2% to target
Overall win rate
30%
+ Follow
#4
MN
Michael Nedelcovych
TD Cowen
Buy
No targeton CHRS
Coverage
—
+ Follow
#5
Ashwani Verma
UBS
Neutral
$1.10+169.5% to target
Coverage
—
+ Follow
CHRS stock forecast FAQ
What is CHRS's average 12-month price target?+
The 2 active firms with a live target average $10.00 for Coherus BioSciences Inc over the next 12 months, ranging from a $10.00 high to a $10.00 low, as of Nov 19, 2026.
Is CHRS stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover CHRS?+
2 active firms have a recognized rating on Coherus BioSciences Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CHRS?+
Among analysts who currently cover CHRS, Douglas Tsao of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #312). Their current call is Buy with a $7.00 target.
What is Coherus BioSciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.20 per share (range $-0.20 – $-0.20) across 1 analysts. Full-year EPS is projected at $-0.90, rising to $-0.62 the following year.
How much revenue is Coherus BioSciences Inc expected to report next quarter?+
Consensus revenue is $19.2M (range $17.3M – $20.5M). Full-year revenue is projected at $56.7M, growing to $87.5M next year.
Have analysts been upgrading or downgrading CHRS lately?+
As of Nov 19, 2026, 2 of 2 active firms rate CHRS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CHRS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.